STOCK TITAN

Praxis Precision Medicines Inc - PRAX STOCK NEWS

Welcome to our dedicated news page for Praxis Precision Medicines (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Praxis Precision Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Praxis Precision Medicines's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.31%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
earnings
Praxis Precision Medicines Inc

Nasdaq:PRAX

PRAX Rankings

PRAX Stock Data

783.71M
11.01M
0.21%
60.89%
3.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About PRAX

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res